Joint Formulary & PAD

Aripiprazole - Bipolar disorder (adults)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Oral solution
  • Oro-dispersible tablets
  • Tablets
Associated Icons :
SPC
Restrictions / Comments :
Important

Oro-dispersible tablets are more cost effective than oral solution. Reserve oral solution for use in patients where the required dose is not available in an oro-dispersible form.

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Aripiprazole
Indication :
Bipolar disorder (adults)
Group Name :
Keywords :
manic episodes, mania, antipsychotics
Brand Names Include :
Abilify
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Committee Recommendations (1)

GENERIC Aripiprazole has been considered by the PCN and has been assigned a BLUE traffic light status.

NOTE - the branded product, Abilify, was considered BLACK at the PCN in May 2017.